A Longitudinal Observational Study of the Natural History and Management of Patientswith Hepatocellular Carcinoma
A 5-Year Study of the Natural History and Management of Patients with Hepatocellular Carcioma (A Type of Liver Cancer)
Sponsor: TARGET PharmaSolutions, Inc.
Enrolling: Male and Female Patients
Study Length: 5 Years
IRB Number: AAAR3667
Contact: Elizabeth Verna, MD: 212-305-3839 / ev77@cumc.columbia.edu
Additional Study Information: Patients will be asked to participate in this research study because they have been diagnosed with hepatocellular carcinoma (HCC) which is a type of liver cancer. By doing this study, researchers hope to: Find out more about patients that have HCC including their age, race/ethnicity, and other medical conditions they may have; learn more about how frequently patients with HCC need to go to the hospital or have surgery; learn about different medications, procedures, and other treatments that are being used to manage HCC; find out how different HCC therapies may affect certain types of patients differently than others; understand the effects of different durations and medicines for HCC therapy in different groups of patients; learn more about the different side effects of HCC treatment in the real world. For example, researchers hope to learn about the number of side effects, how side effects are treated, and the number or type of side effects that may cause patients to stop HCC treatment. Understand changes that may be happening in the liver or to the HCC throughout the body by looking at reports such as those for scans, tests, and biopsies; better understand how different treatments affect what patients are able to do and how they feel; learn about the long-term effects of HCC treatment on patients health; to create a Biorepository Specimen Bank with blood samples and liver or tumor tissue samples.
Elizabeth Verna, MD
Do You Qualify?
Are you 18 years or older? Yes No
Have you been diagnosed with hepatocellular carcinoma (HCC), a type of liver cancer? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Elizabeth Verna, MD